290 related articles for article (PubMed ID: 15972483)
1. posttranslational modification of recombinant Plasmodium falciparum apical membrane antigen 1: impact on functional immune responses to a malaria vaccine candidate.
Giersing B; Miura K; Shimp R; Wang J; Zhou H; Orcutt A; Stowers A; Saul A; Miller LH; Long C; Singh S
Infect Immun; 2005 Jul; 73(7):3963-70. PubMed ID: 15972483
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria.
Malkin EM; Diemert DJ; McArthur JH; Perreault JR; Miles AP; Giersing BK; Mullen GE; Orcutt A; Muratova O; Awkal M; Zhou H; Wang J; Stowers A; Long CA; Mahanty S; Miller LH; Saul A; Durbin AP
Infect Immun; 2005 Jun; 73(6):3677-85. PubMed ID: 15908397
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara.
Thera MA; Coulibaly D; Kone AK; Guindo AB; Traore K; Sall AH; Diarra I; Daou M; Traore IM; Tolo Y; Sissoko M; Niangaly A; Arama C; Baby M; Kouriba B; Sissoko MS; Sagara I; Toure OB; Dolo A; Diallo DA; Remarque E; Chilengi R; Noor R; Sesay S; Thomas A; Kocken CH; Faber BW; Imoukhuede EB; Leroy O; Doumbo OK
Malar J; 2016 Aug; 15(1):442. PubMed ID: 27577237
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
Lalitha PV; Biswas S; Pillai CR; Saxena RK
Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
[TBL] [Abstract][Full Text] [Related]
5. Immune responses in mice induced by prime-boost schemes of the Plasmodium falciparum apical membrane antigen 1 (PfAMA1)-based DNA, protein and recombinant modified vaccinia Ankara vaccines.
Miao J; Li X; Liu Z; Xue C; Bujard H; Cui L
Vaccine; 2006 Sep; 24(37-39):6187-98. PubMed ID: 16806600
[TBL] [Abstract][Full Text] [Related]
6. A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits.
Remarque EJ; Faber BW; Kocken CH; Thomas AW
Infect Immun; 2008 Jun; 76(6):2660-70. PubMed ID: 18378635
[TBL] [Abstract][Full Text] [Related]
7. Production, quality control, stability and pharmacotoxicity of cGMP-produced Plasmodium falciparum AMA1 FVO strain ectodomain expressed in Pichia pastoris.
Faber BW; Remarque EJ; Kocken CH; Cheront P; Cingolani D; Xhonneux F; Jurado M; Haumont M; Jepsen S; Leroy O; Thomas AW
Vaccine; 2008 Nov; 26(48):6143-50. PubMed ID: 18804135
[TBL] [Abstract][Full Text] [Related]
8. Strain-specific Plasmodium falciparum growth inhibition among Malian children immunized with a blood-stage malaria vaccine.
Laurens MB; Kouriba B; Bergmann-Leitner E; Angov E; Coulibaly D; Diarra I; Daou M; Niangaly A; Blackwelder WC; Wu Y; Cohen J; Ballou WR; Vekemans J; Lanar DE; Dutta S; Diggs C; Soisson L; Heppner DG; Doumbo OK; Plowe CV; Thera MA
PLoS One; 2017; 12(3):e0173294. PubMed ID: 28282396
[TBL] [Abstract][Full Text] [Related]
9. Identification of Plasmodium falciparum reticulocyte binding protein homologue 5-interacting protein, PfRipr, as a highly conserved blood-stage malaria vaccine candidate.
Ntege EH; Arisue N; Ito D; Hasegawa T; Palacpac NMQ; Egwang TG; Horii T; Takashima E; Tsuboi T
Vaccine; 2016 Nov; 34(46):5612-5622. PubMed ID: 27692771
[TBL] [Abstract][Full Text] [Related]
10. Overcoming antigenic diversity by enhancing the immunogenicity of conserved epitopes on the malaria vaccine candidate apical membrane antigen-1.
Dutta S; Dlugosz LS; Drew DR; Ge X; Ababacar D; Rovira YI; Moch JK; Shi M; Long CA; Foley M; Beeson JG; Anders RF; Miura K; Haynes JD; Batchelor AH
PLoS Pathog; 2013; 9(12):e1003840. PubMed ID: 24385910
[TBL] [Abstract][Full Text] [Related]
11. Use of immunodampening to overcome diversity in the malarial vaccine candidate apical membrane antigen 1.
Harris KS; Adda CG; Khore M; Drew DR; Valentini-Gatt A; Fowkes FJ; Beeson JG; Dutta S; Anders RF; Foley M
Infect Immun; 2014 Nov; 82(11):4707-17. PubMed ID: 25156737
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys.
Pichyangkul S; Tongtawe P; Kum-Arb U; Yongvanitchit K; Gettayacamin M; Hollingdale MR; Limsalakpetch A; Stewart VA; Lanar DE; Dutta S; Angov E; Ware LA; Bergmann-Leitner ES; House B; Voss G; Dubois MC; Cohen JD; Fukuda MM; Heppner DG; Miller RS
Vaccine; 2009 Dec; 28(2):452-62. PubMed ID: 19857448
[TBL] [Abstract][Full Text] [Related]
13. Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine.
Ouattara A; Mu J; Takala-Harrison S; Saye R; Sagara I; Dicko A; Niangaly A; Duan J; Ellis RD; Miller LH; Su XZ; Plowe CV; Doumbo OK
Malar J; 2010 Jun; 9():175. PubMed ID: 20565971
[TBL] [Abstract][Full Text] [Related]
14. Specificity of the protective antibody response to apical membrane antigen 1.
Hodder AN; Crewther PE; Anders RF
Infect Immun; 2001 May; 69(5):3286-94. PubMed ID: 11292751
[TBL] [Abstract][Full Text] [Related]
15. Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria.
Polley SD; Mwangi T; Kocken CH; Thomas AW; Dutta S; Lanar DE; Remarque E; Ross A; Williams TN; Mwambingu G; Lowe B; Conway DJ; Marsh K
Vaccine; 2004 Dec; 23(5):718-28. PubMed ID: 15542195
[TBL] [Abstract][Full Text] [Related]
16. In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response.
Kennedy MC; Wang J; Zhang Y; Miles AP; Chitsaz F; Saul A; Long CA; Miller LH; Stowers AW
Infect Immun; 2002 Dec; 70(12):6948-60. PubMed ID: 12438374
[TBL] [Abstract][Full Text] [Related]
17. Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth.
Bruder JT; Stefaniak ME; Patterson NB; Chen P; Konovalova S; Limbach K; Campo JJ; Ettyreddy D; Li S; Dubovsky F; Richie TL; King CR; Long CA; Doolan DL
Vaccine; 2010 Apr; 28(18):3201-10. PubMed ID: 20188680
[TBL] [Abstract][Full Text] [Related]
18. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.
Polhemus ME; Magill AJ; Cummings JF; Kester KE; Ockenhouse CF; Lanar DE; Dutta S; Barbosa A; Soisson L; Diggs CL; Robinson SA; Haynes JD; Stewart VA; Ware LA; Brando C; Krzych U; Bowden RA; Cohen JD; Dubois MC; Ofori-Anyinam O; De-Kock E; Ballou WR; Heppner DG
Vaccine; 2007 May; 25(21):4203-12. PubMed ID: 17442466
[TBL] [Abstract][Full Text] [Related]
19. Antibody response of naturally infected individuals to recombinant Plasmodium vivax apical membrane antigen-1.
Rodrigues MH; Rodrigues KM; Oliveira TR; Cômodo AN; Rodrigues MM; Kocken CH; Thomas AW; Soares IS
Int J Parasitol; 2005 Feb; 35(2):185-92. PubMed ID: 15710439
[TBL] [Abstract][Full Text] [Related]
20. Malaria vaccine-related benefits of a single protein comprising Plasmodium falciparum apical membrane antigen 1 domains I and II fused to a modified form of the 19-kilodalton C-terminal fragment of merozoite surface protein 1.
Faber BW; Remarque EJ; Morgan WD; Kocken CH; Holder AA; Thomas AW
Infect Immun; 2007 Dec; 75(12):5947-55. PubMed ID: 17938224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
